AUSTIN, Texas, Dec. 19, 2025 /PRNewswire/ — Feel30 , a telehealth platform specializing in testosterone replacement therapy and men’s hormone optimization, has AUSTIN, Texas, Dec. 19, 2025 /PRNewswire/ — Feel30 , a telehealth platform specializing in testosterone replacement therapy and men’s hormone optimization, has

Feel30 Launches Austin-Based Telehealth Platform for Evidence-Proven TRT & Integrated At-Home Phlebotomy Services

AUSTIN, Texas, Dec. 19, 2025 /PRNewswire/ — Feel30 , a telehealth platform specializing in testosterone replacement therapy and men’s hormone optimization, has introduced a care model designed to improve access to clinically supervised treatment. Based in Austin, the service provides evidence-based TRT, enclomiphene treatment, and erectile dysfunction medications prescribed by licensed U.S. clinicians, with medications fulfilled through licensed U.S. pharmacies.

Feel30 launches national telehealth TRT with at-home nurse blood draws.

Feel30 was founded on 22nd February 2025, by entrepreneur Thomas Phillips, who sought to address common problems in traditional hormone care, including long wait times, multiple in-person lab visits, slow or delayed pharmacy compounding, confusing pricing with hidden fees, and rigid schedules. 

Internal data from Feel30’s early patient population shows that 40% of men seek evaluation primarily due to sustained low energy compared to earlier stages of life, while 30% enroll after relocating to a new state and needing continuity of TRT care.

Service features include transparent all-inclusive pricing, quarterly at-home nurse blood draws, home or in-clinic lab flexibility, unlimited clinician consultations, discreet pharmacy fulfillment, and scheduling on patients’ terms.

The initial laboratory panel costs $99 to $129 and includes the lab test, the at-home nurse visit or in-clinic option, the medical intake, and the clinician review. Ongoing treatment starts at $199 to $235 per month and includes medication, quarterly at-home nurse blood draws, unlimited clinician consultations, follow-up care, medication management, and discreet shipping. There are no upsells or hidden fees.

The care process begins with a comprehensive blood panel to evaluate testosterone levels and related biomarkers. Patients can receive at-home nurse visits as early as the next day, with optional in-clinic laboratory testing available. Feel30’s licensed clinicians review results and issue prescriptions only when medically appropriate and aligned with established guidelines. Most patients complete their initial evaluation within 48 to 72 hours.

Feel30 is one of the only national TRT providers offering quarterly at-home phlebotomy included in the base membership price, positioning it as a leading option for men seeking convenient, medically supervised hormone therapy.

According to established Endocrine Society guidelines, testosterone therapy should only be prescribed after laboratory testing confirms low testosterone. Testosterone levels naturally decline with age, and clinically low levels may be associated with symptoms like fatigue, reduced libido, decreased muscle mass, increased body fat, and lower motivation. Enclomiphene may be used to increase endogenous testosterone production while preserving fertility.

“Many men experience delays in hormone evaluation because of limited appointment availability or the inconvenience of accessing laboratory services,” said Anneliese Cadena, AGNP-C, board-certified Nurse Practitioner and consultant for Feel30. “Telehealth combined with at-home diagnostics allows timely evaluation and guideline-based prescribing with ongoing medical oversight.”
Telehealth continues to increase in men’s hormone care as patients seek faster evaluation and more flexible access to licensed clinicians. Integrated care models allow clinicians to assess laboratory data remotely, prescribe treatment, and follow up with patients.

Media Contact: Thomas Phillips, support@feel30.com, 833-545-1589

**About Feel30** Feel30 is based in Austin, Texas. The platform provides evidence-based testosterone therapy, enclomiphene treatment, and men’s health services with all-inclusive pricing, at-home lab testing with nurse visits, unlimited clinician support, and fast U.S. pharmacy fulfillment. The company’s mission is to make evidence-based hormone care clearer, faster, and more accessible for busy men nationwide who refuse to wait.

Cision View original content:https://www.prnewswire.com/news-releases/feel30-launches-austin-based-telehealth-platform-for-evidence-proven-trt–integrated-at-home-phlebotomy-services-302646836.html

SOURCE Feel30

Market Opportunity
TRUST AI Logo
TRUST AI Price(TRT)
$0.2402
$0.2402$0.2402
0.00%
USD
TRUST AI (TRT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Octav Integrates Chainlink to Deliver Independent Onchain NAV for DeFi

Octav Integrates Chainlink to Deliver Independent Onchain NAV for DeFi

Octav integrates Chainlink oracles to deliver neutral on-chain NAV, restoring trust during volatile DeFi markets. October shocks exposed DeFi operating without
Share
Crypto News Flash2025/12/21 17:51
SEC Final Judgments on FTX Executives Filed

SEC Final Judgments on FTX Executives Filed

The SEC has filed proposed final consent judgments against former FTX executives. Key figures involved include Caroline Ellison, Gary Wang, and Nishad Singh.
Share
CoinLive2025/12/21 18:06
SHIB Price Drops as Leadership Concerns Grow

SHIB Price Drops as Leadership Concerns Grow

The post SHIB Price Drops as Leadership Concerns Grow appeared on BitcoinEthereumNews.com. Shiba Inu investors uneasy as Kusama’s silence fuels leadership concerns. SHIB slid 13% in three days, retracing from $0.00001484 to $0.00001305. Shibarium exploit and Kusama’s absence have weighed on investor trust. Shiba Inu investors are voicing concerns about the project’s long-term direction as leadership uncertainty and slow ecosystem progress erode confidence.  The token, which rallied from its meme-coin origins to become the second-largest meme asset by market cap, counts more than 1.5 million holders worldwide. But as SHIB matures, the gap between early hype and current delivery has widened.  The project’s transition into an “ecosystem coin” with spin-off projects and Shibarium, its layer-2 network, once raised expectations. Analysts now point to internal challenges as the main factor holding SHIB back from fulfilling that potential. Kusama’s Silence Adds to Instability Central to the debate is the role of Shytoshi Kusama, Shiba Inu’s pseudonymous lead developer. Investors are concerned about the intermittent disappearance of the project’s lead developer, who repeatedly takes unannounced social media breaks.  For instance, Kusama went silent on X for over a month before resurfacing this week amid growing speculation that he had abandoned the Shiba Inu project.  Kusama returned shortly after the Shibarium bridge suffered an exploit worth around $3 million. However, he did not directly address the issue but only reassured Shiba Inu community members of his commitment to advancing the project.  Although most community members didn’t complain about Kusama’s anonymity in the project’s initial stages, his recent behavior has raised concerns. Many are beginning to develop trust issues, particularly because nobody could reveal the SHIB developer’s identity for the past five years. He has conducted all communications under pseudonyms. SHIB Price Action Reflects Sentiment Shift Market reaction has mirrored the doubts. SHIB, which spiked 26% at the start of September, has since reversed. Over the last…
Share
BitcoinEthereumNews2025/09/18 04:13